AL
PTLA

Airain Ltd’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Airain Ltd’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$766K Buy
+13,643
New +$546K 0.03% 460

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Airain Ltd's PTLA Position: Q2 2017 in Review

Airain Ltd opened a new position in Portola Pharmaceuticals, Inc. (PTLA) in Q2 2017: 13,643 shares worth $766K. The stake represents 0.03% of the portfolio and ranks #460 among its holdings.

206 funds tracked by Wall St. Rank hold PTLA as of Q2 2017.

  • Airain Ltd held 13,643 shares of Portola Pharmaceuticals, Inc. worth $766K as of Q2 2017.
  • Portola Pharmaceuticals, Inc. was a new Airain Ltd position in Q2 2017.
  • Portola Pharmaceuticals, Inc. made up 0.03% of Airain Ltd's portfolio in Q2 2017, its #460 holding.
  • 206 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2017.

Based on Airain Ltd's 13F filing for Q2 2017, filed 8 Aug 2017.